StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30220% above fair value
$133.72+0.91 (+0.69%)

Close on Nov 20, 2026Market cap $329.91BP/E 107.0Yield 2.45%

Merck gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Merck's gross profit for the twelve months ending Jun 30, 2026 was $48.57B, down 0.3% year over year. For fiscal 2025 it was $48.63B, down 0.7% from the year before. Over ten years it grew 7.1% a year on average. The highest annual figure on record is $48.98B in fiscal 2024.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$48.63B-0.7%
FY2024Dec 31, 2024$48.98B+11.3%
FY2023Dec 31, 2023$43.99B+5.1%
FY2022Dec 31, 2022$41.87B+19.4%
FY2021Dec 31, 2021$35.08B+25.7%
FY2020Dec 31, 2020$27.90B+2.9%
FY2019Dec 31, 2019$27.11B-5.8%
FY2018Dec 31, 2018$28.79B+5.8%
FY2017Dec 31, 2017$27.21B+5.6%
FY2016Dec 31, 2016$25.78B+4.9%
FY2015Dec 31, 2015$24.56B-3.6%
FY2014Dec 31, 2014$25.47B-5.9%
FY2013Dec 31, 2013$27.08B-12.1%
FY2012Dec 31, 2012$30.82B-1.1%
FY2011Dec 31, 2011$31.18B+13.0%
FY2010Dec 31, 2010$27.59B+49.9%
FY2009Dec 31, 2009$18.41B+0.8%
FY2008Dec 31, 2008$18.27B+1.2%
FY2007Dec 31, 2007$18.06B–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.21B-0.3%
Q1 FY2026Mar 31, 2026$12.09B-0.2%
Q4 FY2025Dec 31, 2025$10.85B-8.0%
Q3 FY2025Sep 30, 2025$13.42B+6.7%
Q2 FY2025Jun 30, 2025$12.25B-1.0%
Q1 FY2025Mar 31, 2025$12.11B-1.0%
Q4 FY2024Dec 31, 2024$11.80B+10.1%
Q3 FY2024Sep 30, 2024$12.58B+7.5%
Q2 FY2024Jun 30, 2024$12.37B+12.3%
Q1 FY2024Mar 31, 2024$12.24B+15.9%
Q4 FY2023Dec 31, 2023$10.72B+7.7%
Q3 FY2023Sep 30, 2023$11.70B+6.1%
Q2 FY2023Jun 30, 2023$11.01B+6.1%
Q1 FY2023Mar 31, 2023$10.56B+0.4%
Q4 FY2022Dec 31, 2022$9.95B+3.1%
Q3 FY2022Sep 30, 2022$11.03B+13.6%
Q2 FY2022Jun 30, 2022$10.38B+25.1%
Q1 FY2022Mar 31, 2022$10.52B+41.6%
Q4 FY2021Dec 31, 2021$9.65B+63.0%
Q3 FY2021Sep 30, 2021$9.70B+22.6%
Q2 FY2021Jun 30, 2021$8.30B+25.6%
Q1 FY2021Mar 31, 2021$7.43B-15.1%
Q4 FY2020Dec 31, 2020$5.92B+129.8%
Q3 FY2020Sep 30, 2020$7.92B-5.8%
Q2 FY2020Jun 30, 2020$6.61B-21.0%
Q1 FY2020Mar 31, 2020$8.75B+12.6%
Q4 FY2019Dec 31, 2019$2.58B-66.6%
Q3 FY2019Sep 30, 2019$8.41B+17.2%
Q2 FY2019Jun 30, 2019$8.36B+18.6%
Q1 FY2019Mar 31, 2019$7.76B+13.3%
Q4 FY2018Dec 31, 2018$7.71B+10.2%
Q3 FY2018Sep 30, 2018$7.18B+2.2%
Q2 FY2018Jun 30, 2018$7.05B+3.4%
Q1 FY2018Mar 31, 2018$6.85B+7.3%
Q4 FY2017Dec 31, 2017$6.99B+5.3%
Q3 FY2017Sep 30, 2017$7.02B-1.5%
Q2 FY2017Jun 30, 2017$6.81B–
Q1 FY2017Mar 31, 2017$6.39B–
Q4 FY2016Dec 31, 2016$6.64B–
Q3 FY2016Sep 30, 2016$7.13B–

More Merck figures

See a number that looks wrong?